Mark Rosenberg, Author at AskBio - Page 5 of 6

AskBio Partners with TPG and Vida Ventures Posted on April 11, 2019 (May 28, 2020) by Mark Rosenberg in News
First Patient Dosed with Gene Therapy in Phase 1/2 Study of ACTUS-101 in Patients with Pompe Disease Posted on January 22, 2019 (May 28, 2020) by Mark Rosenberg in News
The Growing Promise of Gene Therapy Approaches Posted on August 30, 2018 (January 3, 2020) by Mark Rosenberg in Event
Asklepios BioPharmaceutical, Inc. Launches New Portfolio Company – Actus Therapeutics, Inc. Posted on December 14, 2017 (May 28, 2020) by Mark Rosenberg in News
AskBio and Columbus Venture Partners Launch Gene Therapy Company Viralgen Posted on October 17, 2017 (May 28, 2020) by Mark Rosenberg in News
NanoCor Announces New Data on Congestive Heart Failure Gene Therapy Posted on September 26, 2017 (May 28, 2020) by Mark Rosenberg in News
Pfizer Aims To Become Industry Leader In Gene Therapy With Acquisition Of Bamboo Therapeutics, Inc. Posted on August 1, 2016 (May 28, 2020) by Mark Rosenberg in News
NanoCor Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) for Carfostin® Posted on April 20, 2016 (January 2, 2020) by Mark Rosenberg in Uncategorized
Baxter to Acquire Chatham Therapeutics Posted on April 2, 2014 (May 28, 2020) by Mark Rosenberg in News
Asklepios BioPharmaceutical Enters Into A Patent License Agreement With Pfizer Posted on September 13, 2010 (May 28, 2020) by Mark Rosenberg in News